All News

A new study found that among 2,200 patients with irritable bowel diseases, 63% encountered financial barriers that led to missed doses of medication.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses ways that digital passports can help ensure patients receive the correct medication.

Sustainable diet habits include behaviors like sticking to a diet plan and avoiding alcohol.

Off-the-shelf cell therapies hold immense promise for revolutionizing precision medicine by offering accessible and affordable treatments. However, overcoming the immune system's rejection and navigating the FDA's approval process are crucial challenges.

Felzartamab granted Breakthrough Designation after a clinical trial showed a significant improvement in late antibody-mediated rejection in kidney transplant recipients compared with placebo.

The partnership will provide plan members with access to digital services aimed at older patients.

Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.

Pending regulatory approval, the two companies will form a new company named NewCo.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses innovations in label design that could lead to improved patient outcomes and less medical errors.

Breakthrough Therapy designation for survodutide was based on preliminary clinical data showing potential improvement in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis over existing therapies.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses scenarios where unclear labeling led to challenges for patient outcomes.

Under the agreement, AstraZeneca will be granted access to CSPC's small molecule candidate, YS2302018, with the goal of treating dyslipidemia and cardiovascular disease.

Approval was based on results from Phase I clinical safety studies, which demonstrated that using three tubes of Ameluz maintained similar safety and systemic exposure levels as one tube in treating actinic keratosis in patients undergoing photodynamic therapy.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses ways to ensure that product labels are easily understood universally.

The locations were spread across 37 different states.

The U.S. healthcare system has undergone significant changes, particularly in the pharmaceutical industry, due to factors like telemedicine, integrated delivery networks, and value-based care. This has challenged traditional sales models and increased the need for more strategic engagement with clinical executives.

The event, part of the #CheckYourFoodTube campaign, was held in Cincinnati, Ohio.

Approval of Cologuard Plus follows results from the BLUE-C study, which demonstrated a 95% sensitivity for detecting colorectal cancer.

Approval for Opdivo was based on results from the CheckMate-77T trial, which demonstrated that the combination significantly improved event-free survival and pathologic complete response in adults with resectable non-small cell lung cancer without EGFR or ALK rearrangements.

From early-stage funding to commercialization, startups must adapt their strategies and messaging to effectively attract investors, build partnerships, and ultimately succeed.

The stop loss is designed to protect against potentially massive costs related to gene therapy treatments.

The campaign is called #BustTheMyth and is aimed at patient education.

Under terms of the deal, Philogen will complete clinical trials for Fibromun, seek approval, and handle manufacturing, with Sun Pharma leading global commercialization.

Priority Review was based on data from the ECHO Phase III trial, which demonstrated that a combination of Calquence, bendamustine, and rituximab reduced the risk of disease progression or death by 27% in patients with previously untreated mantle cell lymphoma.

A Q&A with Dr. Ken Dychtwald, Recipient of the McKinsey Award for his Harvard Business Review article, “It’s Time to Retire Retirement.”

The ROGUE device is being developed thanks to a $34.9 million grant from ARPA-H.

Marketed as a biosimilar to Stelara, approval of Otulfi was based on clinical data demonstrating comparable efficacy in treating inflammatory conditions such as Crohn disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis.

New facilities are expected to focus on manufacturing next-generation medicines and biologic medicines.